<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Postural tachycardia syndrome</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Postural tachycardia syndrome</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Postural tachycardia syndrome</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">William P Cheshire, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Michael J Aminoff, MD, DSc</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Richard P Goddeau, Jr, DO, FAHA</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 14, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3280508773"><span class="h1">INTRODUCTION AND TERMINOLOGY</span><span class="headingEndMark"> — </span>Postural tachycardia syndrome (POTS) is a disorder characterized by orthostatic intolerance. Orthostatic intolerance describes an abnormal autonomic response causing symptoms that develop while sustaining an upright posture. Orthostatic intolerance symptoms include lightheadedness, dizziness, blurring or fading of vision, generalized weakness, fatigue, palpitations, mental clouding, anxiety, nausea, dyspnea, or headache. Disorders characterized by orthostatic intolerance include  (<a class="graphic graphic_figure graphicRef130448" href="/z/d/graphic/130448.html" rel="external">figure 1</a> and <a class="graphic graphic_table graphicRef130450" href="/z/d/graphic/130450.html" rel="external">table 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Postural tachycardia syndrome</strong> – The clinical syndrome of POTS includes intermittent symptoms of orthostatic intolerance accompanied by excessive tachycardia without arterial hypotension. POTS is also called "postural orthostatic tachycardia syndrome," but the word "orthostatic" may be omitted. POTS has previously been described as neurocirculatory asthenia, mitral valve prolapse syndrome, hyperdynamic beta adrenergic state, irritable heart, soldier's heart, Da Costa syndrome, and irritable heart syndrome [<a href="#rid1">1</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Orthostatic hypotension</strong> – This disorder is defined by a sustained reduction of systolic blood pressure of at least 20 mmHg or diastolic blood pressure of 10 mmHg, with or without symptoms during the assessment, within three minutes of standing or head-up tilt [<a href="#rid2">2</a>]. Orthostatic hypotension is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5103.html" rel="external">"Mechanisms, causes, and evaluation of orthostatic hypotension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reflex syncope</strong> (also called vasovagal syncope, neurally mediated syncope, or neurocardiogenic syncope) – Symptoms include a distinct prodrome of facial pallor, sweating, nausea, yawning, or hyperventilation culminating in a transient loss of consciousness and postural tone [<a href="#rid2">2,3</a>]. Reflex syncope often occurs during prolonged standing and may coexist with POTS. In a study of 300 patients with POTS, 18 (6 percent) also had syncope during tilt-table testing [<a href="#rid4">4</a>]. Reflex syncope is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/1050.html" rel="external">"Reflex syncope in adults and adolescents: Clinical presentation and diagnostic evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic isolated orthostatic intolerance</strong> – Chronic symptoms of orthostatic intolerance may occur in patients without excessive tachycardia [<a href="#rid5">5</a>]. This condition of chronic orthostatic intolerance is often considered to be on the POTS spectrum broadly interpreted, as patients may have a modest elevation in heart rate.</p><p></p><p>This topic discusses POTS. Other conditions characterized by orthostatic intolerance are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5103.html" rel="external">"Mechanisms, causes, and evaluation of orthostatic hypotension"</a> and  <a class="medical medical_review" href="/z/d/html/5105.html" rel="external">"Treatment of orthostatic and postprandial hypotension"</a> and  <a class="medical medical_review" href="/z/d/html/1050.html" rel="external">"Reflex syncope in adults and adolescents: Clinical presentation and diagnostic evaluation"</a> and  <a class="medical medical_review" href="/z/d/html/111958.html" rel="external">"Reflex syncope in adults and adolescents: Treatment"</a>.)</p><p class="headingAnchor" id="H240758182"><span class="h1">PATHOPHYSIOLOGY</span></p><p class="headingAnchor" id="H1729962129"><span class="h2">Normal orthostatic response</span><span class="headingEndMark"> — </span>The ability to stand erect against the force of gravity requires sufficient muscular strength, a firm skeletal frame, a sense of balance, consciousness, and modulation of cardiovascular autonomic function to compensate for the downward displacement of 500 to 800 mL of blood to the abdomen and lower extremities [<a href="#rid3">3,6</a>].</p><p>The autonomic nervous system responds to the unloading of carotid sinus and aortic arch baroreceptors during standing by increasing cardiovascular sympathetic adrenergic outflow and decreasing cardiovagal parasympathetic outflow [<a href="#rid7">7</a>]. The sympathetic response increases peripheral vasoconstrictor tone, cardiac rate, and inotropic state. The parasympathetic response is withdrawal of vagal tone from the heart, which increases heart rate [<a href="#rid8">8</a>]. Also important for orthostatic tolerance is the skeletal "muscle pump," whereby rhythmic contraction of lower extremity and abdominal muscles squeezes capacitance vessels and assists the return of venous blood to the heart [<a href="#rid9">9</a>]. These combined responses maintain cardiac output for perfusion of the brain and other organs.</p><p class="headingAnchor" id="H2127811232"><span class="h2">Mechanisms</span><span class="headingEndMark"> — </span>In POTS, a variety of pathophysiologic conditions may lead to a final common pathway of orthostatic intolerance with tachycardia. More than one mechanism may be present in a given patient. Potential underlying causes include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypovolemia and deconditioning</strong> – In the majority of POTS patients, intravascular volume is reduced; this contributes to decreased venous return to the heart, reflex tachycardia, and orthostatic intolerance [<a href="#rid10">10,11</a>]. A deconditioned state further contributes to hypovolemic symptoms because a higher heart rate is needed to sustain cardiac output.</p><p></p><p class="bulletIndent1">POTS is associated with low blood volume [<a href="#rid12">12</a>], decreased cardiac left-ventricular mass [<a href="#rid13">13</a>], and reduced cardiac stroke volume [<a href="#rid14">14</a>], a pattern remarkably similar to that in people who are highly deconditioned or who have been at prolonged bed rest [<a href="#rid15">15</a>]. As an example, in one study, healthy volunteers placed at sustained bed rest for two weeks developed orthostatic intolerance along with a 17 percent reduction in plasma volume and a 5 percent reduction in cardiac mass [<a href="#rid16">16</a>].</p><p></p><p class="bulletIndent1">Many patients with POTS avoid physical activity because of symptoms of orthostatic intolerance, exacerbating a deconditioned state that may further contribute to hypovolemic symptoms. Reconditioning efforts often improve but do not fully restore function or eliminate symptoms in POTS, suggesting that additional factors are present [<a href="#rid17">17</a>]. Among them, somatic hypervigilance, in which patients perceive mild or routine sensory information as intense or distressing, can sustain a deconditioned state [<a href="#rid15">15</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuroendocrine dysfunction</strong> – Some patients with POTS have evidence of increased cardiovascular adrenergic function separate from tachycardia, suggesting that POTS represents a hyperadrenergic state. Such patients have an increased blood pressure overshoot during the Valsalva maneuver [<a href="#rid18">18</a>]. On average, patients with POTS have higher catecholamine levels than healthy controls [<a href="#rid19">19</a>], and some have been found to have an increase in norepinephrine on standing [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Some patients with POTS have a functional or acquired deficiency in the norepinephrine transporter membrane protein. In these patients, increased synaptic norepinephrine leads to excessive adrenergic responses to physiologic stimuli [<a href="#rid21">21</a>].</p><p></p><p class="bulletIndent1">Studies have found that patients with POTS have on average lower levels of plasma renin and aldosterone [<a href="#rid10">10,22</a>] and higher levels of plasma angiotensin II [<a href="#rid23">23</a>]; these findings are in contrast with what is expected in patients with hypovolemia and suggest angiotensin II receptor subtype imbalance as a potential theory for POTS [<a href="#rid24">24</a>]. Correspondingly, higher levels of angiotensin II may reflect deficiency in the vasodilatory effects of endothelial nitric oxide also found in some POTS patients [<a href="#rid8">8,22,25,26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neuropathy</strong> – A small-fiber neuropathy may be present in up to one-half of POTS cases and contributes to dysautonomia. Abnormalities in sudomotor testing were reported in 43 to 63 percent of POTS patients and were associated with gastrointestinal symptoms such as nausea, bloating, constipation, and abdominal pain [<a href="#rid20">20,27-29</a>]. In another study, POTS patients had reduced resting muscle sympathetic nerve activity and a delayed cardiovascular adrenergic response to hypotensive challenge suggesting impairment of adrenergic nerve function [<a href="#rid30">30</a>]. Additionally, some POTS patients have reduced intraepidermal nerve fiber density or small nerve fiber morphologic changes indicating selective impairment of autonomic fibers [<a href="#rid29">29,31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Autoimmunity</strong> – An autoimmune basis for a small number of POTS patients has been linked to the observation of orthostatic symptoms following a viral illness [<a href="#rid32">32,33</a>]. Additionally, autoantibodies to the ganglionic nicotinic acetylcholine receptor [<a href="#rid20">20,34</a>] and alpha-1 adrenergic, beta-1/2 adrenergic, and angiotensin II type 1 receptors [<a href="#rid35">35-38</a>] have been detected in a few patients. These autoantibodies are speculated to impair effective peripheral vasoconstriction leading to a compensatory tachycardia [<a href="#rid36">36,38</a>].</p><p></p><p class="bulletIndent1">However, the presence of autoantibodies in POTS should be interpreted cautiously. Low antibody levels were reported in small numbers of cases, some without adequate controls or physiologic specificity, and the levels of antibodies did not correlate with the severity of POTS [<a href="#rid20">20</a>]. In one study, more than half of patients who reported onset of POTS following a viral illness also recalled a lifelong tendency toward orthostatic symptoms, suggesting the illness may have unmasked or exacerbated a preexisting subclinical diathesis [<a href="#rid39">39</a>]<strong>.</strong></p><p></p><p class="bulletIndent1">Multiple case series have reported orthostatic intolerance or POTS as a delayed manifestation of COVID-19 infection in some patients who had no prior history of symptoms of orthostatic intolerance [<a href="#rid40">40-45</a>]. POTS and other orthostatic intolerance syndromes have also been reported following COVID-19 vaccination [<a href="#rid46">46,47</a>]. However, a large cohort study of more than 280,000 patients who received the COVID-19 vaccination and more than 12,000 who developed a COVID-19 infection found that the risk of POTS and related syndromes within 90 days of exposure was more than five-fold higher for those who developed infection than those who received vaccination (odds ratio 5.35, 95% CI 5.1-5.7) [<a href="#rid48">48</a>].</p><p></p><p class="headingAnchor" id="H1597062199"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Patients with POTS are typically young (between the ages of 15 and 50 years) and female (5:1 predominance of females to males) [<a href="#rid49">49-51</a>]. A large cross-sectional, community-based online survey of patients identified that half of patients first developed symptoms in adolescence, and more than 90 percent were white females of childbearing age [<a href="#rid39">39</a>].</p><p></p><p>Some low-quality data estimate the prevalence of POTS to be between 0.1 and 1 percent [<a href="#rid52">52</a>].</p><p class="headingAnchor" id="H3487578108"><span class="h1">CLINICAL FEATURES</span><span class="headingEndMark"> — </span>The hallmark symptoms of orthostatic intolerance in patients with POTS occur in the upright posture. Additionally, a number of less-specific nonorthostatic symptoms are common in POTS  (<a class="graphic graphic_table graphicRef130449" href="/z/d/graphic/130449.html" rel="external">table 2</a>).</p><p>These symptoms are disabling in many patients. Patients with POTS experience impairments in quality of life across multiple domains of physical and social functioning. Short-Form Health Survey assessment of POTS patients found functional limitations comparable to those of patients with chronic obstructive pulmonary disease or congestive heart failure, conditions that generally affect patients older than those with POTS [<a href="#rid53">53</a>]. In one series of 94 patients with a mean age of 34 years, 25 percent were disabled and unable to work [<a href="#rid53">53</a>].</p><p class="headingAnchor" id="H2957888804"><span class="h2">Orthostatic intolerance</span><span class="headingEndMark"> — </span>Symptoms of orthostatic intolerance are brought on by standing and relieved by sitting down. They typically include lightheadedness, palpitations, fading vision, presyncope, difficulty concentrating, and headache. Some patients will also report dyspnea, chest pain, nausea, tremulousness, flushing, or blurred vision [<a href="#rid39">39,54,55</a>]. The orthostatic headache that may occur in POTS consists of dull occipital and cervical trapezius pain (so-called "coat hanger headache") while in the upright position and is relieved by sitting [<a href="#rid54">54</a>].</p><p>Orthostatic symptoms often vary by day, week, and month:</p><p class="bulletIndent1"><span class="glyph">●</span>Orthostatic symptoms are more pronounced when standing still; walking is generally better tolerated. As examples, patients may be unable to stand in a checkout line at a store, in the kitchen long enough to prepare a meal, or in conversation at social gatherings without frequently taking steps or shifting weight to activate the skeletal muscle pump to improve venous return to the heart.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Orthostatic symptoms and heart rates are more pronounced during conditions of increased orthostatic stress or vasodilation. Prolonged recumbency can lead to deconditioning and exacerbation of symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms tend to be worse during early morning hours, in hot weather, during menses, and during febrile illness or stress. Patients with POTS are almost always unable to tolerate standing while taking a warm shower, and many must sit down to bathe. After a shower they may have to lie down and rest.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients may report exaggerated orthostatic symptoms from dehydration or medications that can lower blood pressure.</p><p></p><p class="headingAnchor" id="H2571682693"><span class="h2">Symptoms unrelated to orthostasis</span><span class="headingEndMark"> — </span>Many patients with POTS also report symptoms that are unrelated to postural changes. Symptoms may be intermittent or constant and include anxiety, fatigue, resting or nocturnal paroxysmal tachycardia, acrocyanosis, chest pain, nausea, bloating, constipation, diarrhea, abdominal pain, headaches, difficulty concentrating, syncope, blurred vision, dry mouth, dry eyes, foot coldness, extremity tingling, cutaneous flushing, or urinary frequency [<a href="#rid39">39,55</a>]. The extensive number and nonspecific nature of these symptoms makes attributing them to a diagnosis of POTS with certainty challenging. (See <a class="local">'Diagnostic approach'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Anxiety</strong> – Anxiety is common in POTS [<a href="#rid56">56,57</a>] but appears phenomenologically distinct from symptoms of generalized anxiety disorder or panic disorder [<a href="#rid58">58,59</a>]. It is characterized by somatic hypervigilance [<a href="#rid53">53,60</a>]. Psychological profiles of patients with POTS have found anxiety appears to be driven by heightened awareness of internal somatic sensations or fear conditioning in anticipation of orthostatic stress, rather than by trait anxiety or neurosis [<a href="#rid59">59,61</a>]. When patients were shown a series of randomly presented neutral, pleasant, or unpleasant images in the supine and upright postures, their emotional responsivity to unpleasant images was greater during head-up tilt, suggesting that increased autonomic reactivity amplified their sense of internal threat [<a href="#rid61">61,62</a>].</p><p></p><p class="bulletIndent1">Measures of increased somatic vigilance, somatic anxiety, and catastrophic thinking correlate with functional disability in POTS [<a href="#rid59">59,60,63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fatigue</strong> – Fatigue is a common symptom among patients with POTS but may be underrecognized, as reports identifying the association vary widely (21 to 93 percent) [<a href="#rid20">20,39,64</a>]. Fatigue may be attributable to orthostatic intolerance and/or exercise intolerance in POTS; however, in many patients, a sense of low energy does not always resolve upon sitting but persists at rest and may recur in cycles lasting for days or weeks at a time [<a href="#rid55">55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cognitive dysfunction</strong> – Neuropsychological testing of patients with POTS has shown mild impairments in attention, cognitive processing speed, memory function, and executive function, even when in seated or supine positions [<a href="#rid56">56</a>]. Selective attention and cognitive processing speed, in particular, are reduced [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1">There is also consistent evidence of mild to moderate depression in POTS. These impairments do not correlate with heart rate changes but have been speculated to be due to high levels of circulating catecholamines or central norepinephrine dysregulation rather than decreased cerebral perfusion [<a href="#rid65">65</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Gastrointestinal disturbances</strong> – Gastrointestinal complaints are common in POTS [<a href="#rid66">66</a>]. They may include nausea, irregular bowel movements, bloating, diarrhea, abdominal pain or cramping, constipation, heartburn, or vomiting [<a href="#rid20">20,67,68</a>]. Irritable bowel syndrome is diagnosed in 30 percent and gastroparesis in 14 percent [<a href="#rid39">39,67</a>]. Nausea and vomiting can also cause hypovolemia and exacerbate orthostatic intolerance symptoms.</p><p></p><p class="bulletIndent1">The mechanism of gastrointestinal symptoms in POTS is not understood but is likely multifactorial. An investigation of splanchnic-mesenteric vasoregulation in 11 patients found an excessive splanchnic blood pooling in POTS patients compared with controls [<a href="#rid69">69</a>]. Intestinal hypomobility resulting from circulating catecholamines also likely plays a role [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sleep disturbances</strong> – Nonrestorative sleep and daytime drowsiness are common and contribute to fatigue and impaired health-related quality of life [<a href="#rid71">71,72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Headache</strong> – Primary headache syndromes including migraine and tension-type headache are common, with prevalence estimates of 35 percent or higher [<a href="#rid20">20,39,73,74</a>]. Central sensitization has been proposed as a contributing factor [<a href="#rid73">73</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overactive bladder</strong> – In a small study of 19 females with POTS who completed a standardized questionnaire for overactive bladder symptoms, 13 met clinical criteria for overactive bladder, with nocturia being the most bothersome symptom, followed by frequency and urgency [<a href="#rid75">75</a>]. It is unclear whether symptoms are from autonomic dysregulation of lower urinary tract function or a consequence of recommending increased oral fluid intake, a common strategy for managing POTS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skin findings</strong> – Some patients with POTS may also have dermatologic manifestation including acrocyanosis, livedo reticularis, Raynaud phenomenon, and various rashes [<a href="#rid76">76,77</a>]. Bier anemic spots (white macules on erythematous background), cyanosis, and urticaria-like eruption (BASCULE) syndrome is a vasomotor dermatosis that has been associated with POTS in several case reports [<a href="#rid78">78-81</a>]. Symptoms are typically present in the lower legs, occur or worsen with standing, and may improve with treatment of POTS symptoms or antihistamines.</p><p></p><p class="headingAnchor" id="H382998290"><span class="h1">DIAGNOSTIC APPROACH</span></p><p class="headingAnchor" id="H1783603705"><span class="h2">Diagnostic criteria</span><span class="headingEndMark"> — </span>The diagnosis of POTS is made by:</p><p class="bulletIndent1"><span class="glyph">●</span>History of symptoms of orthostatic intolerance with or without systemic symptoms</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Correlation of symptoms with a sustained increase in upright heart rate by at least 30 beats/minute (40 beats/minute for patients under the age of 20 years) within 10 minutes of standing or head-up tilt, without orthostatic hypotension [<a href="#rid2">2,54,82-84</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Autonomic testing to correlate symptoms with heart rate changes, confirm the diagnosis, and assess the degree of objective signs of orthostatic intolerance</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other diagnostic testing as needed to exclude alternative diagnoses or confounding concomitant conditions (see <a class="local">'Differential diagnosis'</a> below)</p><p></p><p class="headingAnchor" id="H12275370"><span class="h2">Clinical evaluation</span><span class="headingEndMark"> — </span>The key physical finding is an excessive rise in resting heart rate within 10 minutes of standing, without decrease in blood pressure. Orthostatic intolerance symptoms should accompany tachycardia.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptomatic orthostatic tachycardia</strong> – In patients with POTS, the heart rate elevation should exceed 30 beats/minute (40 beats/minute in patients under 20 years of age) above a resting baseline while supine or seated.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Baseline heart rate and blood pressure should be measured after at least 5 minutes of rest supine and again after one minute of standing. If initial values are nondiagnostic, repeating the measurement of vital signs at 3, 5, or 10 minutes is often informative. The patient should be asked to stand quietly and still.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Pulse oximeter devices are useful for measuring orthostatic heart rates to display values much faster than the traditional method of counting the pulse over 15 seconds and multiplying by 4. The heart rate can vary greatly from moment to moment, so average rather than transient peak values should be recorded.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with POTS should experience orthostatic intolerance symptoms during testing for orthostatic tachycardia. (See <a class="local">'Orthostatic intolerance'</a> above.)</p><p></p><p class="bulletIndent1">A transient increase in heart rate during the first 20 seconds of standing is expected in healthy persons. In patients with POTS, heart rate increases at 30 to 60 seconds and may continue to gradually increase during standing. Additionally, an asymptomatic increase in heart rate by 30 or more beats/minute upon standing is common in healthy adolescents, and 5 percent may have a heart rate increase beyond 40 beats/minute. Because normative heart rate values are different for adolescents, an increase of at least 40 beats/minute is necessary for a diagnosis of POTS.</p><p></p><p class="bulletIndent1">Postural elevations in heart rate without symptoms of orthostatic intolerance are insufficient to make the diagnosis of POTS [<a href="#rid85">85-88</a>]. In the absence of orthostatic symptoms, such an increase represents benign tachycardia [<a href="#rid89">89</a>]. In one study, the threshold of an increase in heart rate of 30 beats/minute at 10 minutes of standing was found to discriminate POTS from healthy controls with only 67 percent specificity [<a href="#rid88">88</a>].</p><p></p><p class="bulletIndent1">In POTS, blood pressure during standing remains normal or may increase. By contrast, in orthostatic hypotension, there is a reduction of standing systolic or diastolic blood pressure by at least 20 or 10 mmHg, respectively.</p><p></p><p class="bulletIndent1">In assessing the magnitude of heart rate changes for the diagnosis of POTS, current medications affecting heart rate, which may be impractical to hold in advance of an outpatient evaluation, should be taken into account. Beta blockers, for example, will suppress the rise in heart rate upon standing and could mask the change diagnostic of POTS. Adrenergic stimulants, norepinephrine transporter and reuptake inhibitors, anticholinergics, and beta-adrenoreceptor agonists can magnify the heart rate increase upon standing and lead to a false diagnosis of POTS [<a href="#rid90">90</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other findings</strong> – During a clinical examination, some patients may demonstrate subtle behaviors suggestive of orthostatic intolerance. While standing, patients may shift their weight back and forth; while sitting, they may entwine their legs [<a href="#rid70">70</a>].</p><p></p><p class="bulletIndent1">Some POTS patients will demonstrate vasomotor changes during standing. Red or purple acrocyanosis, typically of the distal lower extremities, becomes evident during standing and may resolve when supine.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Neurologic examination is normal in POTS.</p><p></p><p class="headingAnchor" id="H3817272239"><span class="h2">Autonomic testing</span><span class="headingEndMark"> — </span>Autonomic testing is useful in the diagnosis of POTS in patients with orthostatic intolerance symptoms and for reassessment of changing symptoms over time. Autonomic testing is more sensitive and specific than random sampling of heart rate during clinical bedside assessment while standing [<a href="#rid91">91</a>].</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tilt-table testing</strong> – Vasomotor adrenergic autonomic testing using a tilt table provides objective evidence of orthostatic intolerance in patients with lightheadedness. It increases the diagnostic yield of assessing tachycardia in patients with POTS and helps exclude orthostatic hypotension. During passive head-up tilt-table testing, full activation of the leg muscles is not needed to support the weight of the body. Thus, it is possible to assess the hemodynamic response to the downward translocation of blood volume without the compensatory influence of the skeletal muscle pump, which may conceal objective signs of orthostatic intolerance during bedside assessment.</p><p></p><p class="bulletIndent1">Testing should include noninvasive beat-to-beat measurement of both heart rate and blood pressure during tilt-table testing, which provides more precise information than does bedside examination [<a href="#rid20">20,92</a>]. Assessment should be based not on random or peak heart rates, but on time-averaged heart rates (from which normative values were derived)  (<a class="graphic graphic_figure graphicRef130451" href="/z/d/graphic/130451.html" rel="external">figure 2</a>) [<a href="#rid20">20,85,92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sudomotor testing</strong> – Sudomotor testing should be performed as a routine component of formal autonomic testing, when available. Approximately half of POTS patients will have neuropathic abnormalities evident by sudomotor testing. Sudomotor deficits are typically postganglionic and patchy in distribution [<a href="#rid20">20,27,29,83</a>].</p><p></p><p class="headingAnchor" id="H356161000"><span class="h2">Laboratory testing</span><span class="headingEndMark"> — </span>Laboratory tests are useful to exclude other or additional causes of orthostatic intolerance symptoms. Because orthostatic intolerance and systemic symptoms are not specific to POTS, we perform routine testing in the initial diagnostic evaluation of patients. This includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Plasma electrolytes</p><p class="bulletIndent1"><span class="glyph">●</span>Complete blood count</p><p class="bulletIndent1"><span class="glyph">●</span>Thyroid function testing</p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiography</p><p></p><p>Additional testing may be considered depending on associated symptoms or history provided. Such testing may include:</p><p class="bulletIndent1"><span class="glyph">●</span>Morning cortisol in the patient with hypotension to exclude adrenal insufficiency. (See  <a class="medical medical_review" href="/z/d/html/161.html" rel="external">"Measurement of cortisol in serum and saliva"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transthoracic echocardiography if heart pump failure is suspected. (See  <a class="medical medical_review" href="/z/d/html/113235.html" rel="external">"Clinical manifestations and diagnosis of advanced heart failure", section on 'Echocardiography'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Supine and standing plasma catecholamines in patients with tachycardia and hypertension. Hyperadrenergic status is associated with an orthostatic increase in systolic blood pressure of at least 10 mmHg or plasma norepinephrine of at least 600 picograms/mL [<a href="#rid19">19,55</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Twenty-four-hour urinary sodium excretion if hypovolemia is suspected. Values less than 100 mEq/24 hours suggest hypovolemia [<a href="#rid20">20,93</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Gastric motility testing in the patient with early satiety or intractable nausea, particularly if the patient cannot maintain adequate oral fluid intake. (See  <a class="medical medical_review" href="/z/d/html/2640.html" rel="external">"Gastroparesis: Etiology, clinical manifestations, and diagnosis", section on 'Assess gastric motility'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tryptase in the patient with prominent flushing to screen for mast cell activation disorder (MCAD). (See  <a class="medical medical_review" href="/z/d/html/15715.html" rel="external">"Mast cell disorders: An overview", section on 'Measure serum tryptase'</a>.)</p><p></p><p>Serologic testing of autoantibodies has low specificity and is not routinely recommended in the evaluation of POTS.</p><p class="headingAnchor" id="H2617161991"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Symptoms of orthostatic intolerance may indicate POTS or alternative orthostatic conditions. Other entities with symptoms that mimic some aspects of the orthostatic intolerance or nonorthostatic systemic symptoms seen in POTS such as lightheadedness, fatigue, or headaches may be excluded by distinguishing clinical features  (<a class="graphic graphic_table graphicRef130450" href="/z/d/graphic/130450.html" rel="external">table 1</a>).</p><p class="headingAnchor" id="H1279067770"><span class="h2">Alternative orthostatic conditions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dehydration</strong> – A diagnosis of POTS should not be made in the patient who is acutely or chronically dehydrated from frequent diarrhea, vomiting, polyuria, or water deprivation. In these patients, the tachycardia may be secondary to intravascular hypovolemia with a reflex increase in heart rate to sustain cardiac output when preload is reduced. The typical hemodynamic profile of dehydration is orthostatic hypotension with compensatory tachycardia. Orthostatic hypotension is an exclusionary criterion for POTS.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic syndromes</strong> – A diagnosis of POTS should not be made before excluding tachycardia caused by medication that has the property of increasing the heart rate. Examples include sympathomimetics, serotonin-norepinephrine reuptake inhibitors, tricyclic antidepressants, <a class="drug drug_general" data-topicid="8787" href="/z/d/drug information/8787.html" rel="external">atomoxetine</a>, and anticholinergics, all of which vary in the degree to which they can influence heart rate in individual patients [<a href="#rid90">90</a>]. The clinician should also inquire about the use of caffeine, psychostimulants, weight loss pills, and decongestants, among others.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Orthostatic hypotension</strong> – Patients with orthostatic hypotension from volume depletion or medications frequently have postural tachycardia with hypotension on testing. Orthostatic hypotension is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5103.html" rel="external">"Mechanisms, causes, and evaluation of orthostatic hypotension"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reflex syncope</strong> – Also called vasovagal, neurally mediated, or neurocardiogenic syncope, this condition is distinct from POTS in that it is an episodic phenomenon, whereas in POTS orthostatic symptoms occur to some degree on a continuous basis. In reflex syncope, bradycardia and hypotension may precede loss of postural tone and transient loss of consciousness.</p><p></p><p class="bulletIndent1">However, the occurrence of syncope does not exclude POTS. Reflex syncope and POTS may coexist as distinct conditions in the same patient [<a href="#rid19">19</a>]. As an example, syncope may also occur in some patients with POTS during prolonged tilt-table testing [<a href="#rid4">4,94</a>]. (See  <a class="medical medical_review" href="/z/d/html/1050.html" rel="external">"Reflex syncope in adults and adolescents: Clinical presentation and diagnostic evaluation"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic isolated orthostatic intolerance</strong> – Some patients may have orthostatic intolerance symptoms without accompanying tachycardia or with a normal heart rate increase [<a href="#rid5">5</a>]. Such patients do not meet diagnostic criteria for POTS and may be described as having chronic isolated orthostatic intolerance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chronic isolated orthostatic tachycardia</strong> – Patients found to have postural tachycardia without symptoms are not diagnosed as having POTS. An excessively elevated heart rate is typically defined as above the 95<sup>th</sup> percentile, meaning that 5 percent of the general population, including many asymptomatic individuals, may have an excessive rise in heart rate when standing (&gt;30 beats/minute, &gt;40 in adolescents) [<a href="#rid89">89</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inappropriate sinus tachycardia</strong> – The syndrome of inappropriate sinus tachycardia is defined by a fast sinus rhythm greater than 100 beats/minute at rest or 90 beats/minute averaged during 24 hours not due to identified underlying causes [<a href="#rid95">95</a>]. In contrast with POTS, the tachycardia occurs at rest rather than in response to the upright posture. Occasionally, inappropriate sinus tachycardia coexists with POTS. (See  <a class="medical medical_review" href="/z/d/html/1074.html" rel="external">"Sinus tachycardia: Evaluation and management", section on 'Inappropriate sinus tachycardia'</a>.)</p><p></p><p class="headingAnchor" id="H3506307934"><span class="h2">Other conditions</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Panic and anxiety disorders</strong> – The somatic symptoms of POTS are phenomenologically distinct from symptoms in patients with primary psychiatric disorders (eg, panic disorder or anxiety disorder). Both present with palpitations, but panic attacks occur spontaneously, whereas the tachycardia in POTS is induced by the upright posture. Symptoms more strongly associated with panic attacks include a feeling of intense fear, a desire to flee, a sense of impending doom, a fear of losing control, a fear of "going crazy," or a fear of dying. (See  <a class="medical medical_review" href="/z/d/html/14628.html" rel="external">"Panic disorder in adults: Epidemiology, clinical manifestations, and diagnosis", section on 'Clinical Manifestations'</a>.)</p><p></p><p class="bulletIndent1">A large online survey of POTS patients found that 77 percent had initially been given a psychiatric diagnosis such as anxiety, panic disorder, or depression. However, once the diagnosis of POTS was made, only 37 percent continued to have a psychiatric diagnosis [<a href="#rid39">39</a>]. Assessment of POTS patients for psychiatric disorders by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria found that they did not have an increased prevalence of anxiety disorders or major depression as compared with the general population, but many had mild depressive symptoms [<a href="#rid96">96</a>].</p><p></p><p class="bulletIndent1">While not commonly used in clinical practice, physiologic responses to drugs or other interventions can also differentiate a psychiatric disorder from the anxiety in POTS. Intravenous infusion of <a class="drug drug_general" data-topicid="8578" href="/z/d/drug information/8578.html" rel="external">isoproterenol</a> or <a class="drug drug_general" data-topicid="10267" href="/z/d/drug information/10267.html" rel="external">sodium lactate</a>, which precipitate panic in patients with panic disorder, did not produce typical symptoms in a series of patients with POTS, although these did cause palpitations, dyspnea, and trembling [<a href="#rid58">58</a>]. Another study compared tilt-table responses in patients with POTS with patients with panic disorder who were comparably tachycardic; the depth of respiration increased in POTS, whereas both the depth and rate of respiration increased in panic disorder. Cardiac output was decreased in POTS but increased in those with panic [<a href="#rid97">97</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypermobile Ehlers-Danlos syndrome (hEDS)</strong> – In addition to classic musculoskeletal and skin findings, patients with the hypermobile type of Ehlers-Danlos syndrome may report orthostatic intolerance or other autonomic symptoms. A number of studies have reported a relationship of POTS with hEDS [<a href="#rid98">98-103</a>].</p><p></p><p class="bulletIndent1">Data associating POTS and hEDS are limited by variations in study methodology, manner of assessment of orthostatic symptoms, and subsequent advances in knowledge about these syndromes. Some patients would no longer be classified as POTS by current heart rate criteria for adolescents [<a href="#rid85">85,104</a>] or as hEDS by the more stringent established criteria for hEDS [<a href="#rid105">105,106</a>]. A consistent finding has been orthostatic symptoms in at least 40 percent of patients with generalized joint hypermobility [<a href="#rid98">98-102,107</a>]. Connective tissue laxity has been hypothesized to affect vascular wall compliance, leading to venous pooling [<a href="#rid101">101</a>], but the mechanism for orthostatic intolerance in a significant proportion of patients with joint hypermobility has not been established. Hypermobile Ehlers-Danlos syndrome is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/5591.html" rel="external">"Clinical manifestations and diagnosis of hypermobile Ehlers-Danlos syndrome and hypermobility spectrum disorder"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mast cell activation syndrome (MCAS)</strong> – Flushing, which can occur in POTS, also occurs in patients with MCAS. In one report of 177 POTS patients, eight patients had episodes of flushing along with elevated urinary methylhistamine levels suggestive of MCAS (serum tryptase levels, a more specific marker of MCAS, were not reported) [<a href="#rid108">108</a>]. However, flushing in MCAS is episodic rather than postural, generalized rather than acral, and cardinal manifestations of MCAS such as urticaria, angioedema, or bronchial airway constriction are not features of POTS [<a href="#rid106">106-111</a>]. A causative association of MCAS with POTS lacks evidence-based support [<a href="#rid106">106</a>]. Mast cell activation syndromes are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15715.html" rel="external">"Mast cell disorders: An overview", section on 'Mast cell activation syndrome'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Spontaneous intracranial hypotension</strong> – Orthostatic headache is one of the symptoms of orthostatic intolerance as well as the hallmark feature of spontaneous intracranial hypotension. Patients with POTS may report orthostatic headaches [<a href="#rid54">54,112</a>]. Additionally, in one instance, orthostatic headaches with postural tachycardia was due to spontaneous intracranial hypotension from cerebrospinal fluid leak [<a href="#rid113">113</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chiari malformation</strong> – While some patients with Chiari I malformation may report dizziness or other symptoms suggestive of orthostatic intolerance, there is no evidence for an association of POTS with the descended cerebellar tonsils in Chiari malformation [<a href="#rid114">114</a>]. (See  <a class="medical medical_review" href="/z/d/html/5101.html" rel="external">"Causes of vertigo", section on 'Chiari malformation'</a>.)</p><p></p><p class="headingAnchor" id="H3581921955"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>The therapeutic strategy for POTS relies on symptom management through intravascular volume expansion, physical exercise, and lifestyle changes as well as compressive garments. Pharmacologic agents may be needed in more severe cases. Data supporting recommendations are limited to small studies using heterogeneous diagnostic criteria and varied duration of follow-up or from expert consensus opinion [<a href="#rid115">115</a>].</p><p class="headingAnchor" id="H2322760704"><span class="h2">Initial treatment strategies</span><span class="headingEndMark"> — </span>We suggest increasing fluid and salt intake and advise an exercise regimen with targeted lifestyle modifications for the initial treatment of most patients with POTS.</p><p class="headingAnchor" id="H2108615387"><span class="h3">Water and salt intake</span><span class="headingEndMark"> — </span>Oral fluid intake should be encouraged to a target of 3 L daily and a daily salt intake of 8 to 12 g of sodium chloride (3.2 to 4.8 g of sodium) [<a href="#rid55">55,84,104,116</a>]. Available sources of sodium include table salt, sports tablets, sports beverages, oral rehydration salts, and some soups. The long-term effects on blood pressure of increased sodium intake in POTS are unknown [<a href="#rid93">93,117</a>].</p><p>Intravenous boluses of 1 to 2 L of normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> can be used for hypovolemic patients unable to tolerate liberalization of fluids by mouth to help improve orthostatic symptoms for up to two days [<a href="#rid118">118-120</a>]. This strategy may be used as a short-term bridge to enable the patient to engage in physical exercise and other lifestyle modifications [<a href="#rid51">51,121</a>]. Long-term administration of intravenous saline infusions through an indwelling central venous port is discouraged because of the potential risks of venous thrombosis, bacteremia, and systemic infections [<a href="#rid90">90,104,116,122</a>].</p><p class="headingAnchor" id="H1254244403"><span class="h3">Exercise</span><span class="headingEndMark"> — </span>Patients with POTS benefit from an incremental program of aerobic exercise. Many patients with POTS are physically deconditioned and others are at risk for deconditioning by restricting their physical activity to manage POTS symptoms [<a href="#rid15">15,55,123</a>].</p><p>Despite intolerance of exercise in the upright position, many patients are successful in beginning an exercise program in a semirecumbent position, such as with a recumbent bicycle, with a rowing machine, or in a swimming pool. Exercise rehabilitation for POTS should include lower extremity resistance strength training, which helps to reduce venous pooling [<a href="#rid15">15</a>]. Supervised training may be needed for patients who cannot adhere to an exercise program on their own or believe exercise to be too difficult [<a href="#rid124">124</a>]. An approach that has worked well starts with training sessions three to four times per week for 30 to 40 minutes per session. During these sessions, exercise intensity is individualized to achieve 70 to 75 percent of maximal predicted heart rate. As fitness improves, patients should be able gradually to increase the duration, intensity, and frequency of exercise and advance to exercising in the upright posture [<a href="#rid125">125</a>].</p><p>The benefits of exercise in POTS have been demonstrated in small studies. In one study involving 31 military recruits with symptoms of orthostatic intolerance, those assigned to an exercise regimen were less likely to report orthostatic symptoms at three months [<a href="#rid126">126</a>]. In another study, 19 patients with POTS assigned to a three-month exercise training program (consisting of 30- to 45-minute sessions two to four times weekly) showed improved cardiovascular responses to exercise, lower heart rates, and faster heart rate recovery after exercise compared with baseline [<a href="#rid127">127</a>]. Among 103 patients who completed a program of mild-to-moderate intensity progressive endurance training, 71 percent went into remission and no longer met the diagnostic criteria for POTS [<a href="#rid125">125</a>].</p><p class="headingAnchor" id="H3729474009"><span class="h3">Lifestyle management</span><span class="headingEndMark"> — </span>Behavioral and environmental changes may help reduce systemic (nonorthostatic) symptoms. The efficacy of these strategies has not been evaluated systematically in POTS patients but may provide adjunctive benefit to many patients. Such strategies include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Encourage patients to be upright as much as possible during the day and to avoid prolonged bedrest, which can lead to further deconditioning.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Manage catastrophizing, anxiety, and functional disability with counseling and cognitive behavioral therapy [<a href="#rid63">63,128</a>]. (See  <a class="medical medical_review" href="/z/d/html/14612.html" rel="external">"Overview of psychotherapies", section on 'Cognitive and behavioral therapies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Develop physical habits to reduce triggering symptoms. As examples, lower extremity muscle tensing, leg crossing, and weight shifting engage the skeletal "muscle pump" to improve venous return and can provide immediate temporary symptom relief.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improve sleep quality by having a consistent bedtime and wake time, not spending time in bed during the day, winding down prior to going to bed, and ensuring that the bedroom environment promotes sleep [<a href="#rid129">129</a>].</p><p></p><p class="headingAnchor" id="H2607375695"><span class="h2">Adjunctive treatment options</span><span class="headingEndMark"> — </span>In patients with severe symptoms and those whose symptoms persist in spite of initial treatment strategies, we add compressive garments and medications to the management regimen. Individual options among choices are guided by patient preferences and concomitant medical comorbidities.</p><p class="headingAnchor" id="H2184931368"><span class="h3">Compressive garments</span><span class="headingEndMark"> — </span>We use graded compressive stockings or abdominal binders to reduce symptoms related to venous pooling. Waist-high stockings at 30 to 40 mmHg or abdominal binders at 10 mmHg ameliorate lower extremity and splanchnic venous pooling, respectively, but higher pressures do not provide further benefit [<a href="#rid130">130</a>].</p><p>Lower-extremity compressive garments avoid risk of adverse effects associated with medications but are not always tolerated, as they can be uncomfortable to wear. The use of an abdominal binder is better tolerated and convenient because it can be applied when the patient is upright and is easily removed at other times [<a href="#rid130">130</a>]. Compression of the abdomen may be more beneficial in reducing venous pooling than compression of the legs because of the higher venous capacitance of the splanchnic mesenteric bed, which is the largest of the body's venous reservoirs, accounting for one-third of the total blood volume [<a href="#rid131">131,132</a>].</p><p class="headingAnchor" id="H2917204588"><span class="h3">Medications</span><span class="headingEndMark"> — </span>The use of medications to treat POTS is based on severity of the patient's symptoms and response to other treatments. We start medications at a low dose and titrate slowly, as patients with POTS are often sensitive to medications, and doses effective for POTS are typically lower than the doses at which these medications are used for other conditions.</p><p>Initial medication choice is guided by targeting the underlying mechanism and by patient medical comorbidities. A general rationale is provided here, with specific drug recommendations listed further below. For most patients, our approach to selecting initial pharmacotherapy includes:</p><p class="bulletIndent1"><span class="glyph">●</span>Beta blockers for patients without contraindicating comorbid medical conditions to reduce orthostatic tachycardia</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vasopressor therapy for patients who have neuropathic (eg, sudomotor or acral vasomotor) symptoms [<a href="#rid20">20,84</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Avoiding medications that inhibit norepinephrine uptake for patients with evidence of a hyperadrenergic state</p><p></p><p>However, there is no specific pharmacologic algorithm that applies to all patients. For an individual patient, it may be necessary to try several approaches in succession. We commonly use beta blockers, <a class="drug drug_general" data-topicid="9651" href="/z/d/drug information/9651.html" rel="external">midodrine</a>, <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a>, or <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">pyridostigmine</a> and reserve the other medications listed below in select severe or refractory cases.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Beta blockers</strong> – Beta adrenergic receptor antagonists can blunt elevations in heart rate and are therefore used frequently in patients with POTS. <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> and <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> have been studied the most in POTS but have not been compared, and there is no consensus as to whether a beta-1 selective or nonselective beta blocker is superior in the treatment of POTS. For some patients, fatigue is a limiting side effect.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">Metoprolol</a> 0.25 to 0.5 mg/kg given twice daily reduced symptoms in nearly 80 percent of children and adolescents in a systematic review of 249 patients [<a href="#rid133">133</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">Propranolol</a> was effective at 20 mg daily in attenuating both tachycardia and symptom burden in a study of 54 patients [<a href="#rid134">134</a>]. A higher dose of 80 mg elicited a greater reduction in heart rate but with less net improvement of symptoms.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Midodrine</strong> – <a class="drug drug_general" data-topicid="9651" href="/z/d/drug information/9651.html" rel="external">Midodrine</a>, an alpha adrenoreceptor agonist, is used at 2.5 to 10 mg three times daily. The medication should be administered in the morning, midday, and late afternoon when the patient is in the upright position.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9651" href="/z/d/drug information/9651.html" rel="external">Midodrine</a> constricts arteriolar and venous capacitance vessels and reduces blood pooling. A crossover study found that midodrine up to 10 mg three times daily improved postural tachycardia in patients with decreased adrenergic vasoconstriction [<a href="#rid135">135</a>]. In a nonblinded trial of 53 adolescents with POTS, midodrine at 2.5 mg once daily was superior to <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> 0.5 mg/kg daily or increased salt and water intake, with 89 percent efficacy during three to six months of follow-up despite the very low dose used [<a href="#rid136">136</a>]. Cutaneous paresthesia is a common side effect. Although supine hypertension is a recognized adverse effect of midodrine when used to treat neurogenic orthostatic hypotension, this seldom occurs when used for POTS [<a href="#rid135">135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fludrocortisone</strong> – The mineralocorticoid <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> is used at 0.05 to 0.2 mg daily. Patients should be monitored for hypokalemia and elevated blood pressure in the supine position while taking fludrocortisone.</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">Fludrocortisone</a> temporarily expands intravascular volume by temporarily promoting renal sodium reabsorption and increases peripheral vascular resistance by sensitizing peripheral blood vessel alpha adrenoreceptors to circulating catecholamines [<a href="#rid137">137,138</a>]. One survey of POTS patients found that fludrocortisone improved nausea in half of 16 POTS patients but without significant improvement in orthostatic symptoms [<a href="#rid139">139</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pyridostigmine</strong> – <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">Pyridostigmine</a> enhances sympathetic ganglionic transmission and is given at doses of 30 to 60 mg up to three times daily.</p><p></p><p class="bulletIndent1">In a small randomized crossover study, POTS patients receiving 30 mg <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">pyridostigmine</a> reported decreased symptoms within four hours and had decreased standing heart rates [<a href="#rid140">140</a>]. In a retrospective study of 300 POTS patients, approximately half reported improvement in orthostatic symptoms on pyridostigmine [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Droxidopa</strong> – <a class="drug drug_general" data-topicid="93840" href="/z/d/drug information/93840.html" rel="external">Droxidopa</a> is a prodrug of norepinephrine that can be administered orally to induce peripheral vasoconstriction. Droxidopa is given 100 mg three times daily, in the morning, midday, and late afternoon, and is best held when patients are recumbent to reduce the risk of supine hypertension. It may be titrated up to 600 mg three times daily for efficacy as symptoms and blood pressure tolerability permit.</p><p></p><p class="bulletIndent1">In a retrospective study of 37 patients with POTS who were treated off-label with <a class="drug drug_general" data-topicid="93840" href="/z/d/drug information/93840.html" rel="external">droxidopa</a> at 100 to 600 mg three times daily, 27 percent reported improved quality of life; however, 41 percent stopped the drug due to adverse effects or ineffectiveness [<a href="#rid141">141</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ivabradine</strong> – Several case series have reported lowering of heart rate and symptomatic improvement in more than half of patients treated with <a class="drug drug_general" data-topicid="101166" href="/z/d/drug information/101166.html" rel="external">ivabradine</a> at 2.5 to 20 mg/day in one to two doses [<a href="#rid142">142-145</a>]. In a small crossover trial of 22 patients with POTS and an elevated baseline norepinephrine level, those assigned to ivabradine given at 2.5 mg to 7.5 mg twice daily (titrated to achieve resting supine heart rate &lt;70 beats/minute) over one month had reduced heart rate and reported improved symptoms compared with those assigned to placebo [<a href="#rid146">146</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Methylphenidate</strong> – As a postsynaptic alpha receptor agonist, <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">methylphenidate</a> releases stored catecholamines. Methylphenidate may be started at 10 mg twice daily and increased as needed every few weeks to 30 mg twice daily. In a retrospective study of 24 POTS patients, methylphenidate given as 10 mg three times daily was associated with improvement of presyncope and fatigue in 14 patients [<a href="#rid147">147</a>]. </p><p></p><p class="headingAnchor" id="H3426290094"><span class="h2">Special circumstances</span></p><p class="headingAnchor" id="H838433584"><span class="h3">Surgery in POTS patients</span><span class="headingEndMark"> — </span>No guidelines or systemic studies are available to direct optimal perioperative management of POTS patients. However, a number of recommendations are offered based on POTS pathophysiology. Intravenous fluid boluses can compensate for preoperative oral fluid restriction. Patients taking <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a> should be monitored for hypokalemia. <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">Epinephrine</a> and combined alpha-beta receptor agonists should be used with caution, as they may worsen tachycardia [<a href="#rid148">148</a>].</p><p>The effects of general anesthetic agents in POTS patients have not been well studied, but there is no evidence that any one agent is superior to another [<a href="#rid148">148</a>]. In a series of 13 POTS patients who underwent surgery with general anesthesia, three patients experienced prolonged intraoperative hypotension, but not tachycardia, that occurred during the course of anesthesia and not at the time of induction [<a href="#rid149">149</a>].</p><p>If prolonged immobilization is necessary postoperatively, early physical therapy is useful to prevent worsening of orthostatic symptoms through deconditioning.</p><p class="headingAnchor" id="H667216090"><span class="h3">POTS and pregnancy</span><span class="headingEndMark"> — </span>Limited data suggest a varied effect of pregnancy on POTS symptoms. During the third trimester of pregnancy, pressure of the uterus against the inferior vena cava can reduce cardiac preload and contribute to orthostatic symptoms. A study of 22 POTS patients who carried pregnancies to term found that orthostatic symptoms worsened in 7, remained unchanged in 3, and improved in 12 [<a href="#rid150">150</a>].</p><p>Nonpharmacologic therapy is appropriate. Salt supplementation should be continued unless contraindicated by hypertension [<a href="#rid151">151</a>]. Exercise regimens and other medication options should be discussed with the patient and her obstetrician prior to implementing.</p><p class="headingAnchor" id="H106933845"><span class="h3">Treatment not recommended</span><span class="headingEndMark"> — </span>Several interventions have previously been used for POTS patients that have been shown to lack efficacy, risk harm, or both.</p><p class="bulletIndent1"><span class="glyph">●</span>Radiofrequency sinus node modification is not recommended for treatment of tachycardia in POTS, as such treatment often worsens symptoms [<a href="#rid104">104</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is insufficient evidence to recommend vagal nerve stimulation in POTS [<a href="#rid152">152</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There is neither evidence nor scientific rationale for the use of endovascular procedures on the thoracic venous system in the treatment of POTS [<a href="#rid153">153</a>].</p><p></p><p class="headingAnchor" id="H1411889964"><span class="h1">PROGNOSIS</span><span class="headingEndMark"> — </span>Most patients with POTS improve with treatment or spontaneously. In one prospective study, orthostatic symptoms improved at one year follow-up in most patients, and more than one-third no longer met tilt-table criteria for POTS [<a href="#rid154">154</a>].</p><p>However, POTS is a chronic condition, and many patients may be subject to occasional flares or recurrences of orthostatic symptoms [<a href="#rid49">49</a>]. In a survey of 502 patients with POTS at a mean of 5.4 years after diagnosis, 19 percent reported complete resolution of symptoms, 51 percent reported persistent but improved symptoms, and 16 percent reported intermittent continued symptoms [<a href="#rid155">155</a>].</p><p>POTS does not increase the risk of mortality [<a href="#rid49">49,116</a>].</p><p class="headingAnchor" id="H449449636"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Definition and terminology</strong> – Postural tachycardia syndrome (POTS) is a disorder of orthostatic tolerance. Orthostatic intolerance describes an abnormal autonomic response causing symptoms that develop while sustaining an upright posture. The clinical syndrome of POTS includes intermittent symptoms of orthostatic intolerance accompanied by excessive tachycardia without arterial hypotension. (See <a class="local">'Introduction and terminology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mechanisms</strong> – In POTS, a variety of pathophysiologic conditions may lead to a final common pathway of orthostatic intolerance with tachycardia. These include hypovolemia and deconditioning, neuroendocrine dysfunction, autonomic neuropathy, and autoimmunity. More than one mechanism may be present in a given patient. (See <a class="local">'Mechanisms'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical features</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Orthostatic intolerance</strong> – Symptoms of orthostatic intolerance in patients with POTS are brought on by standing and are relieved by sitting down. They typically include lightheadedness, palpitations, fading of vision, presyncope, and headache. (See <a class="local">'Clinical features'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Nonorthostatic symptoms</strong> – Many patients with POTS also report symptoms that are unrelated to postural changes. Symptoms may be intermittent or constant and include anxiety, fatigue, resting or nocturnal paroxysmal tachycardia, and acrocyanosis. Anxiety is common in POTS but appears phenomenologically distinct from symptoms of generalized anxiety disorder or panic disorder. (See <a class="local">'Symptoms unrelated to orthostasis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of POTS is made by (see <a class="local">'Diagnostic criteria'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>History of symptoms of orthostatic intolerance with or without systemic symptoms</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Correlation of symptoms with a sustained increase in upright heart rate by at least 30 beats/minute (40 beats/minute for patients under the age of 20 years) within 10 minutes of standing or head-up tilt, without orthostatic hypotension</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Autonomic testing to correlate symptoms with heart rate changes, confirm the diagnosis, and assess the degree of objective signs of orthostatic intolerance</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other diagnostic testing as needed to exclude alternative diagnoses or confounding concomitant conditions</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Initial conservative management</strong> – The therapeutic strategy for POTS relies on symptom management. For most patients with POTS, we suggest conservative interventions such as increasing fluid and salt intake, a regular exercise regimen, and targeted lifestyle modifications (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Initial treatment strategies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adjunctive treatments</strong> – In patients with severe symptoms and those whose symptoms persist in spite of initial treatment strategies, we add compressive garments and medications to the management regimen. Individual options among choices is guided by patient preferences and concomitant medical comorbidities. (See <a class="local">'Adjunctive treatment options'</a> above.)</p><p></p><p class="bulletIndent1">There is no specific pharmacologic algorithm that applies to all patients. We commonly use beta blockers, <a class="drug drug_general" data-topicid="9651" href="/z/d/drug information/9651.html" rel="external">midodrine</a>, <a class="drug drug_general" data-topicid="8455" href="/z/d/drug information/8455.html" rel="external">fludrocortisone</a>, or <a class="drug drug_general" data-topicid="9838" href="/z/d/drug information/9838.html" rel="external">pyridostigmine</a> and reserve the other medications listed above in select severe or refractory cases. (See <a class="local">'Medications'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prognosis</strong> – Most patients with POTS improve with treatment or spontaneously. However, many patients may be subject to occasional flares or recurrences of orthostatic symptoms. (See <a class="local">'Prognosis'</a> above.)</p><p></p><p class="headingAnchor" id="H1188566786"><span class="h1">ACKNOWLEDGMENTS</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Horacio Kaufmann, MD and Roy Freeman, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Streeten DH. Orthostatic intolerance. A historical introduction to the pathophysiological mechanisms. Am J Med Sci 1999; 317:78.</a></li><li><a class="nounderline abstract_t">Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res 2011; 21:69.</a></li><li><a class="nounderline abstract_t">Cheshire WP Jr. Syncope. Continuum (Minneap Minn) 2017; 23:335.</a></li><li><a class="nounderline abstract_t">Kanjwal K, Sheikh M, Karabin B, et al. Neurocardiogenic syncope coexisting with postural orthostatic tachycardia syndrome in patients suffering from orthostatic intolerance: a combined form of autonomic dysfunction. Pacing Clin Electrophysiol 2011; 34:549.</a></li><li><a class="nounderline abstract_t">Boris JR, Huang J, Bernadzikowski T. Orthostatic heart rate does not predict symptomatic burden in pediatric patients with chronic orthostatic intolerance. Clin Auton Res 2020; 30:19.</a></li><li><a class="nounderline abstract_t">Sprangers RL, Wesseling KH, Imholz AL, et al. Initial blood pressure fall on stand up and exercise explained by changes in total peripheral resistance. J Appl Physiol (1985) 1991; 70:523.</a></li><li><a class="nounderline abstract_t">Kaufmann H, Norcliffe-Kaufmann L, Palma JA. Baroreflex Dysfunction. N Engl J Med 2020; 382:163.</a></li><li><a class="nounderline abstract_t">Tanaka H, Sjöberg BJ, Thulesius O. Cardiac output and blood pressure during active and passive standing. Clin Physiol 1996; 16:157.</a></li><li><a class="nounderline abstract_t">Borst C, van Brederode JF, Wieling W, et al. Mechanisms of initial blood pressure response to postural change. Clin Sci (Lond) 1984; 67:321.</a></li><li><a class="nounderline abstract_t">Raj SR, Biaggioni I, Yamhure PC, et al. Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome. Circulation 2005; 111:1574.</a></li><li><a class="nounderline abstract_t">Jacob G, Biaggioni I, Mosqueda-Garcia R, et al. Relation of blood volume and blood pressure in orthostatic intolerance. Am J Med Sci 1998; 315:95.</a></li><li><a class="nounderline abstract_t">Jacob G, Robertson D, Mosqueda-Garcia R, et al. Hypovolemia in syncope and orthostatic intolerance role of the renin-angiotensin system. Am J Med 1997; 103:128.</a></li><li><a class="nounderline abstract_t">Fu Q, Vangundy TB, Galbreath MM, et al. Cardiac origins of the postural orthostatic tachycardia syndrome. J Am Coll Cardiol 2010; 55:2858.</a></li><li><a class="nounderline abstract_t">Masuki S, Eisenach JH, Johnson CP, et al. Excessive heart rate response to orthostatic stress in postural tachycardia syndrome is not caused by anxiety. J Appl Physiol (1985) 2007; 102:896.</a></li><li><a class="nounderline abstract_t">Joyner MJ, Masuki S. POTS versus deconditioning: the same or different? Clin Auton Res 2008; 18:300.</a></li><li><a class="nounderline abstract_t">Levine BD, Zuckerman JH, Pawelczyk JA. Cardiac atrophy after bed-rest deconditioning: a nonneural mechanism for orthostatic intolerance. Circulation 1997; 96:517.</a></li><li><a class="nounderline abstract_t">Jacob G, Biaggioni I. Idiopathic orthostatic intolerance and postural tachycardia syndromes. Am J Med Sci 1999; 317:88.</a></li><li><a class="nounderline abstract_t">Sandroni P, Novak V, Opfer-Gehrking TL, et al. Mechanisms of blood pressure alterations in response to the Valsalva maneuver in postural tachycardia syndrome. Clin Auton Res 2000; 10:1.</a></li><li><a class="nounderline abstract_t">Garland EM, Raj SR, Black BK, et al. The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome. Neurology 2007; 69:790.</a></li><li><a class="nounderline abstract_t">Thieben MJ, Sandroni P, Sletten DM, et al. Postural orthostatic tachycardia syndrome: the Mayo clinic experience. Mayo Clin Proc 2007; 82:308.</a></li><li><a class="nounderline abstract_t">Shannon JR, Flattem NL, Jordan J, et al. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency. N Engl J Med 2000; 342:541.</a></li><li><a class="nounderline abstract_t">Mar PL, Raj SR. Neuronal and hormonal perturbations in postural tachycardia syndrome. Front Physiol 2014; 5:220.</a></li><li><a class="nounderline abstract_t">Stewart JM, Glover JL, Medow MS. Increased plasma angiotensin II in postural tachycardia syndrome (POTS) is related to reduced blood flow and blood volume. Clin Sci (Lond) 2006; 110:255.</a></li><li><a class="nounderline abstract_t">Nagiub M, Moskowitz W, Fortunato J. Systematic literature review of pathophysiology of postural orthostatic tachycardia syndrome (angiotensin II receptor subtype imbalance theory). Prog Pediatr Cardiol 2018; 50:50.</a></li><li><a class="nounderline abstract_t">Stewart JM, Nafday A, Ocon AJ, et al. Cutaneous constitutive nitric oxide synthase activation in postural tachycardia syndrome with splanchnic hyperemia. Am J Physiol Heart Circ Physiol 2011; 301:H704.</a></li><li><a class="nounderline abstract_t">Stewart JM, Medow MS, Minson CT, Taneja I. Cutaneous neuronal nitric oxide is specifically decreased in postural tachycardia syndrome. Am J Physiol Heart Circ Physiol 2007; 293:H2161.</a></li><li><a class="nounderline abstract_t">Peltier AC, Garland E, Raj SR, et al. Distal sudomotor findings in postural tachycardia syndrome. Clin Auton Res 2010; 20:93.</a></li><li><a class="nounderline abstract_t">Al-Shekhlee A, Lindenberg JR, Hachwi RN, Chelimsky TC. The value of autonomic testing in postural tachycardia syndrome. Clin Auton Res 2005; 15:219.</a></li><li><a class="nounderline abstract_t">Gibbons CH, Bonyhay I, Benson A, et al. Structural and functional small fiber abnormalities in the neuropathic postural tachycardia syndrome. PLoS One 2013; 8:e84716.</a></li><li><a class="nounderline abstract_t">Jacob G, Diedrich L, Sato K, et al. Vagal and Sympathetic Function in Neuropathic Postural Tachycardia Syndrome. Hypertension 2019; 73:1087.</a></li><li><a class="nounderline abstract_t">Singer W, Spies JM, McArthur J, et al. Prospective evaluation of somatic and autonomic small fibers in selected autonomic neuropathies. Neurology 2004; 62:612.</a></li><li><a class="nounderline abstract_t">Ruzieh M, Batizy L, Dasa O, et al. The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review. Scand Cardiovasc J 2017; 51:243.</a></li><li><a class="nounderline abstract_t">Sandroni P, Low PA. Other autonomic neuropathies associated with ganglionic antibody. Auton Neurosci 2009; 146:13.</a></li><li><a class="nounderline abstract_t">Vernino S, Low PA, Fealey RD, et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000; 343:847.</a></li><li><a class="nounderline abstract_t">Yu X, Li H, Murphy TA, et al. Angiotensin II Type 1 Receptor Autoantibodies in Postural Tachycardia Syndrome. J Am Heart Assoc 2018; 7.</a></li><li><a class="nounderline abstract_t">Fedorowski A, Li H, Yu X, et al. Antiadrenergic autoimmunity in postural tachycardia syndrome. Europace 2017; 19:1211.</a></li><li><a class="nounderline abstract_t">Li J, Zhang Q, Liao Y, et al. The value of acetylcholine receptor antibody in children with postural tachycardia syndrome. Pediatr Cardiol 2015; 36:165.</a></li><li><a class="nounderline abstract_t">Gunning WT 3rd, Kvale H, Kramer PM, et al. Postural Orthostatic Tachycardia Syndrome Is Associated With Elevated G-Protein Coupled Receptor Autoantibodies. J Am Heart Assoc 2019; 8:e013602.</a></li><li><a class="nounderline abstract_t">Shaw BH, Stiles LE, Bourne K, et al. The face of postural tachycardia syndrome - insights from a large cross-sectional online community-based survey. J Intern Med 2019; 286:438.</a></li><li><a class="nounderline abstract_t">Kanjwal K, Jamal S, Kichloo A, Grubb BP. New-onset Postural Orthostatic Tachycardia Syndrome Following Coronavirus Disease 2019 Infection. J Innov Card Rhythm Manag 2020; 11:4302.</a></li><li><a class="nounderline abstract_t">Miglis MG, Prieto T, Shaik R, et al. A case report of postural tachycardia syndrome after COVID-19. Clin Auton Res 2020; 30:449.</a></li><li><a class="nounderline abstract_t">Shouman K, Vanichkachorn G, Cheshire WP, et al. Autonomic dysfunction following COVID-19 infection: an early experience. Clin Auton Res 2021; 31:385.</a></li><li><a class="nounderline abstract_t">Goodman BP, Khoury JA, Blair JE, Grill MF. COVID-19 Dysautonomia. Front Neurol 2021; 12:624968.</a></li><li><a class="nounderline abstract_t">Larsen NW, Stiles LE, Shaik R, et al. Characterization of autonomic symptom burden in long COVID: A global survey of 2,314 adults. Front Neurol 2022; 13.</a></li><li><a class="nounderline abstract_t">Blitshteyn S, Whitelaw S. Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients. Immunol Res 2021; 69:205.</a></li><li><a class="nounderline abstract_t">Reddy S, Reddy S, Arora M. A Case of Postural Orthostatic Tachycardia Syndrome Secondary to the Messenger RNA COVID-19 Vaccine. Cureus 2021; 13:e14837.</a></li><li><a class="nounderline abstract_t">Park J, Kim S, Lee J, An JY. A case of transient POTS following COVID-19 vaccine. Acta Neurol Belg 2022; 122:1081.</a></li><li><a class="nounderline abstract_t">Kwan AC, Ebinger JE, Wei J, et al. Apparent Risks of Postural Orthostatic Tachycardia Syndrome Diagnoses After COVID-19 Vaccination and SARS-Cov-2 Infection. Nat Cardiovasc Res 2022; 1:1187.</a></li><li><a class="nounderline abstract_t">Arnold AC, Ng J, Raj SR. Postural tachycardia syndrome - Diagnosis, physiology, and prognosis. Auton Neurosci 2018; 215:3.</a></li><li><a class="nounderline abstract_t">Hamrefors V, Spahic JM, Nilsson D, et al. Syndromes of orthostatic intolerance and syncope in young adults. Open Heart 2017; 4:e000585.</a></li><li><a class="nounderline abstract_t">Boris JR, Moak JP. Pediatric Postural Orthostatic Tachycardia Syndrome: Where We Stand. Pediatrics 2022; 150.</a></li><li><a class="nounderline abstract_t">Robertson D. The epidemic of orthostatic tachycardia and orthostatic intolerance. Am J Med Sci 1999; 317:75.</a></li><li><a class="nounderline abstract_t">Benrud-Larson LM, Dewar MS, Sandroni P, et al. Quality of life in patients with postural tachycardia syndrome. Mayo Clin Proc 2002; 77:531.</a></li><li><a class="nounderline abstract_t">Benarroch EE. Postural tachycardia syndrome: a heterogeneous and multifactorial disorder. Mayo Clin Proc 2012; 87:1214.</a></li><li><a class="nounderline abstract_t">Low PA, Sandroni P, Joyner M, Shen WK. Postural tachycardia syndrome (POTS). J Cardiovasc Electrophysiol 2009; 20:352.</a></li><li><a class="nounderline abstract_t">Raj V, Opie M, Arnold AC. Cognitive and psychological issues in postural tachycardia syndrome. Auton Neurosci 2018; 215:46.</a></li><li><a class="nounderline abstract_t">Anderson JW, Lambert EA, Sari CI, et al. Cognitive function, health-related quality of life, and symptoms of depression and anxiety sensitivity are impaired in patients with the postural orthostatic tachycardia syndrome (POTS). Front Physiol 2014; 5:230.</a></li><li><a class="nounderline abstract_t">Khurana RK. Experimental induction of panic-like symptoms in patients with postural tachycardia syndrome. Clin Auton Res 2006; 16:371.</a></li><li><a class="nounderline abstract_t">Owens AP, Low DA, Iodice V, et al. The genesis and presentation of anxiety in disorders of autonomic overexcitation. Auton Neurosci 2017; 203:81.</a></li><li><a class="nounderline abstract_t">Benrud-Larson LM, Sandroni P, Haythornthwaite JA, et al. Correlates of functional disability in patients with postural tachycardia syndrome: preliminary cross-sectional findings. Health Psychol 2003; 22:643.</a></li><li><a class="nounderline abstract_t">Norcliffe-Kaufmann L, Palma JA, Martinez J, et al. Fear conditioning as a pathogenic mechanism in the postural tachycardia syndrome. Brain 2022; 145:3763.</a></li><li><a class="nounderline abstract_t">Owens AP, Low DA, Critchley HD, Mathias CJ. Emotional orienting during interoceptive threat in orthostatic intolerance: Dysautonomic contributions to psychological symptomatology in the postural tachycardia syndrome and vasovagal syncope. Auton Neurosci 2018; 212:42.</a></li><li><a class="nounderline abstract_t">Junghans-Rutelonis AN, Craner JR, Ale CM, et al. Youth with Chronic Pain and Postural Orthostatic Tachycardia Syndrome (POTS): Treatment Mediators of Improvement in Functional Disability. J Clin Psychol Med Settings 2018; 25:471.</a></li><li><a class="nounderline abstract_t">Okamoto LE, Raj SR, Peltier A, et al. Neurohumoral and haemodynamic profile in postural tachycardia and chronic fatigue syndromes. Clin Sci (Lond) 2012; 122:183.</a></li><li><a class="nounderline abstract_t">Arnold AC, Haman K, Garland EM, et al. Cognitive dysfunction in postural tachycardia syndrome. Clin Sci (Lond) 2015; 128:39.</a></li><li><a class="nounderline abstract_t">Mehr SE, Barbul A, Shibao CA. Gastrointestinal symptoms in postural tachycardia syndrome: a systematic review. Clin Auton Res 2018; 28:411.</a></li><li><a class="nounderline abstract_t">Wang LB, Culbertson CJ, Deb A, et al. Gastrointestinal dysfunction in postural tachycardia syndrome. J Neurol Sci 2015; 359:193.</a></li><li><a class="nounderline abstract_t">DiBaise JK, Harris LA, Goodman B. Postural Tachycardia Syndrome (POTS) and the GI Tract: A Primer for the Gastroenterologist. Am J Gastroenterol 2018; 113:1458.</a></li><li><a class="nounderline abstract_t">Tani H, Singer W, McPhee BR, et al. Splanchnic-mesenteric capacitance bed in the postural tachycardia syndrome (POTS). Auton Neurosci 2000; 86:107.</a></li><li><a class="nounderline abstract_t">Cheshire WP Jr, Goldstein DS. The physical examination as a window into autonomic disorders. Clin Auton Res 2018; 28:23.</a></li><li><a class="nounderline abstract_t">Miglis MG, Barwick F. Sleep disorders in patients with postural tachycardia syndrome: A review of the literature and guide for clinicians. Auton Neurosci 2018; 215:62.</a></li><li><a class="nounderline abstract_t">Bagai K, Song Y, Ling JF, et al. Sleep disturbances and diminished quality of life in postural tachycardia syndrome. J Clin Sleep Med 2011; 7:204.</a></li><li><a class="nounderline abstract_t">Cook GA Jr, Sandroni P. Management of headache and chronic pain in POTS. Auton Neurosci 2018; 215:37.</a></li><li><a class="nounderline abstract_t">Ray JC, Pham X, Foster E, et al. The prevalence of headache disorders in Postural Tachycardia Syndrome: A systematic review and meta-analysis of the literature. Cephalalgia 2022; 42:1274.</a></li><li><a class="nounderline abstract_t">Kaufman MR, Chang-Kit L, Raj SR, et al. Overactive bladder and autonomic dysfunction: Lower urinary tract symptoms in females with postural tachycardia syndrome. Neurourol Urodyn 2017; 36:610.</a></li><li><a class="nounderline abstract_t">Huang H, Deb A, Culbertson C, et al. Dermatological Manifestations of Postural Tachycardia Syndrome Are Common and Diverse. J Clin Neurol 2016; 12:75.</a></li><li><a class="nounderline abstract_t">Stewart JM. Pooling in chronic orthostatic intolerance: arterial vasoconstrictive but not venous compliance defects. Circulation 2002; 105:2274.</a></li><li><a class="nounderline abstract_t">El Nemnom P, Lauwerys B, Marot L, et al. Bier anemic spots, cyanosis, and urticaria-like eruption (BASCULE) syndrome: Report of two new cases and literature review. Pediatr Dermatol 2020; 37:864.</a></li><li><a class="nounderline abstract_t">Baurens N, Briand C, Giovannini-Chami L, et al. Case Report, Practices Survey and Literature Review of an Under-Recognized Pediatric Vascular Disorder: The BASCULE Syndrome. Front Pediatr 2022; 10:849914.</a></li><li><a class="nounderline abstract_t">Bessis D, Jeziorski É, Rigau V, et al. Bier anaemic spots, cyanosis with urticaria-like eruption (BASCULE) syndrome: a new entity? Br J Dermatol 2016; 175:218.</a></li><li><a class="nounderline abstract_t">Liu C, Wong ITY, Au S. BASCULE syndrome in a young woman with postural orthostatic tachycardia syndrome. CMAJ 2022; 194:E1382.</a></li><li><a class="nounderline abstract_t">Schondorf R, Low PA. Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia? Neurology 1993; 43:132.</a></li><li><a class="nounderline abstract_t">Khurana RK. Orthostatic intolerance and orthostatic tachycardia: a heterogeneous disorder. Clin Auton Res 1995; 5:12.</a></li><li><a class="nounderline abstract_t">Mar PL, Raj SR. Postural Orthostatic Tachycardia Syndrome: Mechanisms and New Therapies. Annu Rev Med 2020; 71:235.</a></li><li><a class="nounderline abstract_t">Singer W, Sletten DM, Opfer-Gehrking TL, et al. Postural tachycardia in children and adolescents: what is abnormal? J Pediatr 2012; 160:222.</a></li><li><a class="nounderline abstract_t">Castro W, Skarin R, Roscelli JD. Orthostatic heart rate and arterial blood pressure changes in normovolemic children. Pediatr Emerg Care 1985; 1:123.</a></li><li><a class="nounderline abstract_t">Dambrink JH, Imholz BP, Karemaker JM, Wieling W. Circulatory adaptation to orthostatic stress in healthy 10-14-year-old children investigated in a general practice. Clin Sci (Lond) 1991; 81:51.</a></li><li><a class="nounderline abstract_t">Plash WB, Diedrich A, Biaggioni I, et al. Diagnosing postural tachycardia syndrome: comparison of tilt testing compared with standing haemodynamics. Clin Sci (Lond) 2013; 124:109.</a></li><li><a class="nounderline abstract_t">Baker J, Kimpinski K. Normal versus abnormal: What normative data tells us about the utility of heart rate in postural tachycardia. Auton Neurosci 2019; 221:102578.</a></li><li><a class="nounderline abstract_t">Cheshire WP. Stimulant medication and postural orthostatic tachycardia syndrome: a tale of two cases. Clin Auton Res 2016; 26:229.</a></li><li><a class="nounderline abstract_t">Cheshire WP, Freeman R, Gibbons CH, et al. Electrodiagnostic Assessment of the Autonomic Nervous System: A Consensus Statement Endorsed by the American Autonomic Society and the International Federation of Clinical Neurophysiology. Clin Neurophysiol 2021.</a></li><li><a class="nounderline abstract_t">Cheshire WP Jr, Goldstein DS. Autonomic uprising: the tilt table test in autonomic medicine. Clin Auton Res 2019; 29:215.</a></li><li><a class="nounderline abstract_t">Cheshire WP. Salt from the autonomic perspective. Auton Neurosci 2022; 239:102970.</a></li><li><a class="nounderline abstract_t">Ojha A, McNeeley K, Heller E, et al. Orthostatic syndromes differ in syncope frequency. Am J Med 2010; 123:245.</a></li><li><a class="nounderline abstract_t">Olshansky B, Sullivan RM. Inappropriate sinus tachycardia. Europace 2019; 21:194.</a></li><li><a class="nounderline abstract_t">Raj V, Haman KL, Raj SR, et al. Psychiatric profile and attention deficits in postural tachycardia syndrome. J Neurol Neurosurg Psychiatry 2009; 80:339.</a></li><li><a class="nounderline abstract_t">Stewart JM, Pianosi P, Shaban MA, et al. Hemodynamic characteristics of postural hyperventilation: POTS with hyperventilation versus panic versus voluntary hyperventilation. J Appl Physiol (1985) 2018; 125:1396.</a></li><li><a class="nounderline abstract_t">Roma M, Marden CL, De Wandele I, et al. Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome. Auton Neurosci 2018; 215:89.</a></li><li><a class="nounderline abstract_t">Gazit Y, Nahir AM, Grahame R, Jacob G. Dysautonomia in the joint hypermobility syndrome. Am J Med 2003; 115:33.</a></li><li><a class="nounderline abstract_t">De Wandele I, Calders P, Peersman W, et al. Autonomic symptom burden in the hypermobility type of Ehlers-Danlos syndrome: a comparative study with two other EDS types, fibromyalgia, and healthy controls. Semin Arthritis Rheum 2014; 44:353.</a></li><li><a class="nounderline abstract_t">Rowe PC, Barron DF, Calkins H, et al. Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome. J Pediatr 1999; 135:494.</a></li><li><a class="nounderline abstract_t">Miglis MG, Schultz B, Muppidi S. Postural tachycardia in hypermobile Ehlers-Danlos syndrome: A distinct subtype? Auton Neurosci 2017; 208:146.</a></li><li><a class="nounderline abstract_t">Wallman D, Weinberg J, Hohler AD. Ehlers-Danlos Syndrome and Postural Tachycardia Syndrome: a relationship study. J Neurol Sci 2014; 340:99.</a></li><li><a class="nounderline abstract_t">Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm 2015; 12:e41.</a></li><li><a class="nounderline abstract_t">Malfait F, Francomano C, Byers P, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet 2017; 175:8.</a></li><li><a class="nounderline abstract_t">Kohn A, Chang C. The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS). Clin Rev Allergy Immunol 2020; 58:273.</a></li><li><a class="nounderline abstract_t">Miller AJ, Stiles LE, Sheehan T, et al. Prevalence of hypermobile Ehlers-Danlos syndrome in postural orthostatic tachycardia syndrome. Auton Neurosci 2020; 224:102637.</a></li><li><a class="nounderline abstract_t">Shibao C, Arzubiaga C, Roberts LJ 2nd, et al. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders. Hypertension 2005; 45:385.</a></li><li><a class="nounderline abstract_t">Tinkle B, Castori M, Berglund B, et al. Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history. Am J Med Genet C Semin Med Genet 2017; 175:48.</a></li><li><a class="nounderline abstract_t">Frieri M. Mast Cell Activation Syndrome. Clin Rev Allergy Immunol 2018; 54:353.</a></li><li><a class="nounderline abstract_t">Valent P, Akin C, Bonadonna P, et al. Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. J Allergy Clin Immunol Pract 2019; 7:1125.</a></li><li><a class="nounderline abstract_t">Mokri B, Low PA. Orthostatic headaches without CSF leak in postural tachycardia syndrome. Neurology 2003; 61:980.</a></li><li><a class="nounderline abstract_t">Kato Y, Hayashi T, Arai N, et al. Spontaneous Intracranial Hypotension Associated with Postural Tachycardia Syndrome. Intern Med 2019; 58:2569.</a></li><li><a class="nounderline abstract_t">Garland EM, Robertson D. Chiari I malformation as a cause of orthostatic intolerance symptoms: a media myth? Am J Med 2001; 111:546.</a></li><li><a class="nounderline abstract_t">Wells R, Elliott AD, Mahajan R, et al. Efficacy of Therapies for Postural Tachycardia Syndrome: A Systematic Review and Meta-analysis. Mayo Clin Proc 2018; 93:1043.</a></li><li><a class="nounderline abstract_t">Miller AJ, Raj SR. Pharmacotherapy for postural tachycardia syndrome. Auton Neurosci 2018; 215:28.</a></li><li><a class="nounderline abstract_t">Stock JM, Chelimsky G, Edwards DG, Farquhar WB. Dietary sodium and health: How much is too much for those with orthostatic disorders? Auton Neurosci 2022; 238:102947.</a></li><li><a class="nounderline abstract_t">Figueroa RA, Arnold AC, Nwazue VC, et al. Acute volume loading and exercise capacity in postural tachycardia syndrome. J Appl Physiol (1985) 2014; 117:663.</a></li><li><a class="nounderline abstract_t">Gordon VM, Opfer-Gehrking TL, Novak V, Low PA. Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome. Clin Auton Res 2000; 10:29.</a></li><li><a class="nounderline abstract_t">Jacob G, Shannon JR, Black B, et al. Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia. Circulation 1997; 96:575.</a></li><li><a class="nounderline abstract_t">Snapper H, Cheshire WP. Oral and intravenous hydration in the treatment of orthostatic hypotension and postural tachycardia syndrome. Auton Neurosci 2022; 238:102951.</a></li><li><a class="nounderline abstract_t">Moak JP, Leong D, Fabian R, et al. Intravenous Hydration for Management of Medication-Resistant Orthostatic Intolerance in the Adolescent and Young Adult. Pediatr Cardiol 2016; 37:278.</a></li><li><a class="nounderline abstract_t">Galbreath MM, Shibata S, VanGundy TB, et al. Effects of exercise training on arterial-cardiac baroreflex function in POTS. Clin Auton Res 2011; 21:73.</a></li><li><a class="nounderline abstract_t">Fu Q, Levine BD. Exercise and non-pharmacological treatment of POTS. Auton Neurosci 2018; 215:20.</a></li><li><a class="nounderline abstract_t">George SA, Bivens TB, Howden EJ, et al. The international POTS registry: Evaluating the efficacy of an exercise training intervention in a community setting. Heart Rhythm 2016; 13:943.</a></li><li><a class="nounderline abstract_t">Winker R, Barth A, Bidmon D, et al. Endurance exercise training in orthostatic intolerance: a randomized, controlled trial. Hypertension 2005; 45:391.</a></li><li><a class="nounderline abstract_t">Shibata S, Fu Q, Bivens TB, et al. Short-term exercise training improves the cardiovascular response to exercise in the postural orthostatic tachycardia syndrome. J Physiol 2012; 590:3495.</a></li><li><a class="nounderline abstract_t">Junghans-Rutelonis AN, Postier A, Warmuth A, et al. Pain Management In Pediatric Patients With Postural Orthostatic Tachycardia Syndrome: Current Insights. J Pain Res 2019; 12:2969.</a></li><li><a class="nounderline abstract_t">Strassheim V, Welford J, Ballantine R, Newton JL. Managing fatigue in postural tachycardia syndrome (PoTS): The Newcastle approach. Auton Neurosci 2018; 215:56.</a></li><li><a class="nounderline abstract_t">Figueroa JJ, Singer W, Sandroni P, et al. Effects of patient-controlled abdominal compression on standing systolic blood pressure in adults with orthostatic hypotension. Arch Phys Med Rehabil 2015; 96:505.</a></li><li><a class="nounderline abstract_t">Rowell LB, Detry JM, Blackmon JR, Wyss C. Importance of the splanchnic vascular bed in human blood pressure regulation. J Appl Physiol 1972; 32:213.</a></li><li><a class="nounderline abstract_t">Bourne KM, Sheldon RS, Hall J, et al. Compression Garment Reduces Orthostatic Tachycardia and Symptoms in Patients With Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol 2021; 77:285.</a></li><li><a class="nounderline abstract_t">Deng X, Zhang Y, Liao Y, Du J. Efficacy of β-Blockers on Postural Tachycardia Syndrome in Children and Adolescents: A Systematic Review and Meta-Analysis. Front Pediatr 2019; 7:460.</a></li><li><a class="nounderline abstract_t">Raj SR, Black BK, Biaggioni I, et al. Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more. Circulation 2009; 120:725.</a></li><li><a class="nounderline abstract_t">Ross AJ, Ocon AJ, Medow MS, Stewart JM. A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome. Clin Sci (Lond) 2014; 126:289.</a></li><li><a class="nounderline abstract_t">Chen L, Wang L, Sun J, et al. Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome. Circ J 2011; 75:927.</a></li><li><a class="nounderline abstract_t">Chobanian AV, Volicer L, Tifft CP, et al. Mineralocorticoid-induced hypertension in patients with orthostatic hypotension. N Engl J Med 1979; 301:68.</a></li><li><a class="nounderline abstract_t">Davies B, Bannester R, Sever P, Wilcox C. The pressor actions of noradrenaline, angiotensin II and saralasin in chronic autonomic failure treated with fludrocortisone. Br J Clin Pharmacol 1979; 8:253.</a></li><li><a class="nounderline abstract_t">Fortunato JE, Wagoner AL, Harbinson RL, et al. Effect of fludrocortisone acetate on chronic unexplained nausea and abdominal pain in children with orthostatic intolerance. J Pediatr Gastroenterol Nutr 2014; 59:39.</a></li><li><a class="nounderline abstract_t">Raj SR, Black BK, Biaggioni I, et al. Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome. Circulation 2005; 111:2734.</a></li><li><a class="nounderline abstract_t">Ruzieh M, Dasa O, Pacenta A, et al. Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome. Am J Ther 2017; 24:e157.</a></li><li><a class="nounderline abstract_t">Gee ME, Watkins AK, Brown JN, Young EJA. Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Systematic Review. Am J Cardiovasc Drugs 2018; 18:195.</a></li><li><a class="nounderline abstract_t">Cheema MA, Zain MA, Ullah W, Cheema K. Is ivabradine a wonder drug for atypical POTS? BMJ Case Rep 2019; 12.</a></li><li><a class="nounderline abstract_t">McDonald C, Frith J, Newton JL. Single centre experience of ivabradine in postural orthostatic tachycardia syndrome. Europace 2011; 13:427.</a></li><li><a class="nounderline abstract_t">Sutton R, Salukhe TV, Franzen-McManus AC, et al. Ivabradine in treatment of sinus tachycardia mediated vasovagal syncope. Europace 2014; 16:284.</a></li><li><a class="nounderline abstract_t">Taub PR, Zadourian A, Lo HC, et al. Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome. J Am Coll Cardiol 2021; 77:861.</a></li><li><a class="nounderline abstract_t">Kanjwal K, Saeed B, Karabin B, et al. Use of methylphenidate in the treatment of patients suffering from refractory postural tachycardia syndrome. Am J Ther 2012; 19:2.</a></li><li><a class="nounderline abstract_t">Ruzieh M, Dziuba M, Hofmann JP, Grubb BP. Surgical and dental considerations in patients with postural tachycardia syndrome. Auton Neurosci 2018; 215:119.</a></li><li><a class="nounderline abstract_t">Rabbitts JA, Groenewald CB, Jacob AK, et al. Postural orthostatic tachycardia syndrome and general anesthesia: a series of 13 cases. J Clin Anesth 2011; 23:384.</a></li><li><a class="nounderline abstract_t">Kanjwal K, Karabin B, Kanjwal Y, Grubb BP. Outcomes of pregnancy in patients with preexisting postural tachycardia syndrome. Pacing Clin Electrophysiol 2009; 32:1000.</a></li><li><a class="nounderline abstract_t">Ruzieh M, Grubb BP. Overview of the management of postural tachycardia syndrome in pregnant patients. Auton Neurosci 2018; 215:102.</a></li><li><a class="nounderline abstract_t">Petelin Gadze Z, Bujan Kovac A, Adamec I, et al. Vagal nerve stimulation is beneficial in postural orthostatic tachycardia syndrome and epilepsy. Seizure 2018; 57:11.</a></li><li><a class="nounderline abstract_t">Gibbons C, Cheshire W, Barboi A, et al. Endovascular procedures for the treatment of autonomic dysfunction. Clin Auton Res 2014; 24:1.</a></li><li><a class="nounderline abstract_t">Kimpinski K, Figueroa JJ, Singer W, et al. A prospective, 1-year follow-up study of postural tachycardia syndrome. Mayo Clin Proc 2012; 87:746.</a></li><li><a class="nounderline abstract_t">Bhatia R, Kizilbash SJ, Ahrens SP, et al. Outcomes of Adolescent-Onset Postural Orthostatic Tachycardia Syndrome. J Pediatr 2016; 173:149.</a></li></ol></div><div id="topicVersionRevision">Topic 5100 Version 27.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10037111" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Orthostatic intolerance. A historical introduction to the pathophysiological mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21431947" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28375909" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Syncope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208233" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Neurocardiogenic syncope coexisting with postural orthostatic tachycardia syndrome in patients suffering from orthostatic intolerance: a combined form of autonomic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31385108" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Orthostatic heart rate does not predict symptomatic burden in pediatric patients with chronic orthostatic intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2022542" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Initial blood pressure fall on stand up and exercise explained by changes in total peripheral resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31914243" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Baroreflex Dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8964133" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Cardiac output and blood pressure during active and passive standing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6467836" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mechanisms of initial blood pressure response to postural change.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15781744" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Renin-aldosterone paradox and perturbed blood volume regulation underlying postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9472908" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Relation of blood volume and blood pressure in orthostatic intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9274896" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Hypovolemia in syncope and orthostatic intolerance role of the renin-angiotensin system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20579544" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cardiac origins of the postural orthostatic tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17110507" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Excessive heart rate response to orthostatic stress in postural tachycardia syndrome is not caused by anxiety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18704621" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : POTS versus deconditioning: the same or different?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9244220" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Cardiac atrophy after bed-rest deconditioning: a nonneural mechanism for orthostatic intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10037112" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Idiopathic orthostatic intolerance and postural tachycardia syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10750636" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mechanisms of blood pressure alterations in response to the Valsalva maneuver in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17709712" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : The hemodynamic and neurohumoral phenotype of postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17352367" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Postural orthostatic tachycardia syndrome: the Mayo clinic experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10684912" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24982638" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Neuronal and hormonal perturbations in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16262605" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Increased plasma angiotensin II in postural tachycardia syndrome (POTS) is related to reduced blood flow and blood volume.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Systematic literature review of pathophysiology of postural orthostatic tachycardia syndrome (angiotensin II receptor subtype imbalance theory)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21642500" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Cutaneous constitutive nitric oxide synthase activation in postural tachycardia syndrome with splanchnic hyperemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17660395" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Cutaneous neuronal nitric oxide is specifically decreased in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20035362" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Distal sudomotor findings in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15944872" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The value of autonomic testing in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24386408" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Structural and functional small fiber abnormalities in the neuropathic postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30879357" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Vagal and Sympathetic Function in Neuropathic Postural Tachycardia Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981179" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prospective evaluation of somatic and autonomic small fibers in selected autonomic neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28738696" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : The role of autoantibodies in the syndromes of orthostatic intolerance: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19058765" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Other autonomic neuropathies associated with ganglionic antibody.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10995864" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29618472" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Angiotensin II Type 1 Receptor Autoantibodies in Postural Tachycardia Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27702852" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Antiadrenergic autoimmunity in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25087056" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The value of acetylcholine receptor antibody in children with postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31495251" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Postural Orthostatic Tachycardia Syndrome Is Associated With Elevated G-Protein Coupled Receptor Autoantibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30861229" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The face of postural tachycardia syndrome - insights from a large cross-sectional online community-based survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33262898" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : New-onset Postural Orthostatic Tachycardia Syndrome Following Coronavirus Disease 2019 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32880754" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A case report of postural tachycardia syndrome after COVID-19.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33860871" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Autonomic dysfunction following COVID-19 infection: an early experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33927679" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : COVID-19 Dysautonomia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Characterization of autonomic symptom burden in long COVID: A global survey of 2,314 adults</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33786700" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Postural orthostatic tachycardia syndrome (POTS) and other autonomic disorders after COVID-19 infection: a case series of 20 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33968543" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : A Case of Postural Orthostatic Tachycardia Syndrome Secondary to the Messenger RNA COVID-19 Vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35725868" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A case of transient POTS following COVID-19 vaccine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37303827" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Apparent Risks of Postural Orthostatic Tachycardia Syndrome Diagnoses After COVID-19 Vaccination and SARS-Cov-2 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29523389" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Postural tachycardia syndrome - Diagnosis, physiology, and prognosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28674628" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Syndromes of orthostatic intolerance and syncope in young adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35773520" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Pediatric Postural Orthostatic Tachycardia Syndrome: Where We Stand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10037110" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : The epidemic of orthostatic tachycardia and orthostatic intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12059122" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Quality of life in patients with postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23122672" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Postural tachycardia syndrome: a heterogeneous and multifactorial disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207771" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Postural tachycardia syndrome (POTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29628432" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cognitive and psychological issues in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25009504" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Cognitive function, health-related quality of life, and symptoms of depression and anxiety sensitivity are impaired in patients with the postural orthostatic tachycardia syndrome (POTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16915526" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Experimental induction of panic-like symptoms in patients with postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27865628" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The genesis and presentation of anxiety in disorders of autonomic overexcitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14640863" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Correlates of functional disability in patients with postural tachycardia syndrome: preliminary cross-sectional findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35802513" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Fear conditioning as a pathogenic mechanism in the postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29519640" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Emotional orienting during interoceptive threat in orthostatic intolerance: Dysautonomic contributions to psychological symptomatology in the postural tachycardia syndrome and vasovagal syncope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29508112" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Youth with Chronic Pain and Postural Orthostatic Tachycardia Syndrome (POTS): Treatment Mediators of Improvement in Functional Disability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21906029" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Neurohumoral and haemodynamic profile in postural tachycardia and chronic fatigue syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25001527" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Cognitive dysfunction in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29549458" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Gastrointestinal symptoms in postural tachycardia syndrome: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26671111" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Gastrointestinal dysfunction in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30072778" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Postural Tachycardia Syndrome (POTS) and the GI Tract: A Primer for the Gastroenterologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11269915" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Splanchnic-mesenteric capacitance bed in the postural tachycardia syndrome (POTS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29294184" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : The physical examination as a window into autonomic disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29773483" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Sleep disorders in patients with postural tachycardia syndrome: A review of the literature and guide for clinicians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21509337" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Sleep disturbances and diminished quality of life in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29929839" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Management of headache and chronic pain in POTS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35469447" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The prevalence of headache disorders in Postural Tachycardia Syndrome: A systematic review and meta-analysis of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26859225" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Overactive bladder and autonomic dysfunction: Lower urinary tract symptoms in females with postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26610893" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Dermatological Manifestations of Postural Tachycardia Syndrome Are Common and Diverse.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12010910" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pooling in chronic orthostatic intolerance: arterial vasoconstrictive but not venous compliance defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32648305" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Bier anemic spots, cyanosis, and urticaria-like eruption (BASCULE) syndrome: Report of two new cases and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35463901" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Case Report, Practices Survey and Literature Review of an Under-Recognized Pediatric Vascular Disorder: The BASCULE Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27016170" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Bier anaemic spots, cyanosis with urticaria-like eruption (BASCULE) syndrome: a new entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36252987" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : BASCULE syndrome in a young woman with postural orthostatic tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8423877" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Idiopathic postural orthostatic tachycardia syndrome: an attenuated form of acute pandysautonomia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7780285" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Orthostatic intolerance and orthostatic tachycardia: a heterogeneous disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31412221" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Postural Orthostatic Tachycardia Syndrome: Mechanisms and New Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21996154" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Postural tachycardia in children and adolescents: what is abnormal?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3842881" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Orthostatic heart rate and arterial blood pressure changes in normovolemic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1649724" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Circulatory adaptation to orthostatic stress in healthy 10-14-year-old children investigated in a general practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22931296" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Diagnosing postural tachycardia syndrome: comparison of tilt testing compared with standing haemodynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31476713" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Normal versus abnormal: What normative data tells us about the utility of heart rate in postural tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26968177" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Stimulant medication and postural orthostatic tachycardia syndrome: a tale of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Electrodiagnostic Assessment of the Autonomic Nervous System: A Consensus Statement Endorsed by the American Autonomic Society and the International Federation of Clinical Neurophysiology</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30838497" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Autonomic uprising: the tilt table test in autonomic medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35257995" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Salt from the autonomic perspective.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20193833" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Orthostatic syndromes differ in syncope frequency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29931244" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Inappropriate sinus tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18977825" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Psychiatric profile and attention deficits in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30138078" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Hemodynamic characteristics of postural hyperventilation: POTS with hyperventilation versus panic versus voluntary hyperventilation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29519641" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Postural tachycardia syndrome and other forms of orthostatic intolerance in Ehlers-Danlos syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12867232" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Dysautonomia in the joint hypermobility syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24968706" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Autonomic symptom burden in the hypermobility type of Ehlers-Danlos syndrome: a comparative study with two other EDS types, fibromyalgia, and healthy controls.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10518084" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Orthostatic intolerance and chronic fatigue syndrome associated with Ehlers-Danlos syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28986003" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Postural tachycardia in hypermobile Ehlers-Danlos syndrome: A distinct subtype?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24685354" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Ehlers-Danlos Syndrome and Postural Tachycardia Syndrome: a relationship study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25980576" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28306229" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The 2017 international classification of the Ehlers-Danlos syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31267471" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : The Relationship Between Hypermobile Ehlers-Danlos Syndrome (hEDS), Postural Orthostatic Tachycardia Syndrome (POTS), and Mast Cell Activation Syndrome (MCAS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31954224" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Prevalence of hypermobile Ehlers-Danlos syndrome in postural orthostatic tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15710782" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28145611" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Hypermobile Ehlers-Danlos syndrome (a.k.a. Ehlers-Danlos syndrome Type III and Ehlers-Danlos syndrome hypermobility type): Clinical description and natural history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25944644" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Mast Cell Activation Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30737190" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14557573" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Orthostatic headaches without CSF leak in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31118385" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Spontaneous Intracranial Hypotension Associated with Postural Tachycardia Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11705431" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Chiari I malformation as a cause of orthostatic intolerance symptoms: a media myth?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29937049" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Efficacy of Therapies for Postural Tachycardia Syndrome: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29753556" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Pharmacotherapy for postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35131651" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Dietary sodium and health: How much is too much for those with orthostatic disorders?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25059240" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Acute volume loading and exercise capacity in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10750641" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Hemodynamic and symptomatic effects of acute interventions on tilt in patients with postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9244228" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Effects of volume loading and pressor agents in idiopathic orthostatic tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35123367" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Oral and intravenous hydration in the treatment of orthostatic hypotension and postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26446285" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Intravenous Hydration for Management of Medication-Resistant Orthostatic Intolerance in the Adolescent and Young Adult.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21103906" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Effects of exercise training on arterial-cardiac baroreflex function in POTS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30001836" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Exercise and non-pharmacological treatment of POTS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26690066" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : The international POTS registry: Evaluating the efficacy of an exercise training intervention in a community setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15699447" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Endurance exercise training in orthostatic intolerance: a randomized, controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22641777" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Short-term exercise training improves the cardiovascular response to exercise in the postural orthostatic tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31802934" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Pain Management In Pediatric Patients With Postural Orthostatic Tachycardia Syndrome: Current Insights.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29519643" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Managing fatigue in postural tachycardia syndrome (PoTS): The Newcastle approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25448247" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Effects of patient-controlled abdominal compression on standing systolic blood pressure in adults with orthostatic hypotension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4550275" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Importance of the splanchnic vascular bed in human blood pressure regulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33478652" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Compression Garment Reduces Orthostatic Tachycardia and Symptoms in Patients With Postural Orthostatic Tachycardia Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31788462" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Efficacy ofβ-Blockers on Postural Tachycardia Syndrome in Children and Adolescents: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19687359" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Propranolol decreases tachycardia and improves symptoms in the postural tachycardia syndrome: less is more.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23978222" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : A double-blind placebo-controlled cross-over study of the vascular effects of midodrine in neuropathic compared with hyperadrenergic postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21301135" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Midodrine hydrochloride is effective in the treatment of children with postural orthostatic tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/449947" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Mineralocorticoid-induced hypertension in patients with orthostatic hypotension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/497092" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : The pressor actions of noradrenaline, angiotensin II and saralasin in chronic autonomic failure treated with fludrocortisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25222805" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Effect of fludrocortisone acetate on chronic unexplained nausea and abdominal pain in children with orthostatic intolerance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15911704" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Acetylcholinesterase inhibition improves tachycardia in postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27563801" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Droxidopa in the Treatment of Postural Orthostatic Tachycardia Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29330767" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Ivabradine for the Treatment of Postural Orthostatic Tachycardia Syndrome: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31005863" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Is ivabradine a wonder drug for atypical POTS?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21062792" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Single centre experience of ivabradine in postural orthostatic tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24072450" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Ivabradine in treatment of sinus tachycardia mediated vasovagal syncope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33602468" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Randomized Trial of Ivabradine in Patients With Hyperadrenergic Postural Orthostatic Tachycardia Syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20460983" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Use of methylphenidate in the treatment of patients suffering from refractory postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29678416" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Surgical and dental considerations in patients with postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21802629" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Postural orthostatic tachycardia syndrome and general anesthesia: a series of 13 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19659618" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Outcomes of pregnancy in patients with preexisting postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29472161" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Overview of the management of postural tachycardia syndrome in pregnant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29529557" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Vagal nerve stimulation is beneficial in postural orthostatic tachycardia syndrome and epilepsy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24178965" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Endovascular procedures for the treatment of autonomic dysfunction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22795533" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : A prospective, 1-year follow-up study of postural tachycardia syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26979650" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Outcomes of Adolescent-Onset Postural Orthostatic Tachycardia Syndrome.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
